On 07 November 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment (HTAC) recommendation for the government financing of remdesivir (100mg lyophilized powder) for adult patients with COVID-19 requiring hospitalization through its inclusion in the Philippine National Formulary (PNF). This HTAC recommendation serves as an update of the interim HTAC recommendation on the procurement and/or continue reading : HTAC Recommendation on the PNF Inclusion of Remdesivir for Adult Patients with COVID-19 Requiring Hospitalization
Evidence brief for 29 October to 04 November 2022
For the period of 29 October 2022 to 04 November 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 29 October – 04 November 2022 Document Preview:
Evidence brief for 22 to 28 October 2022
For the period of 22 to 28 October 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 22 – 28 October 2022 Document Preview: